Based in Cambridge, MA, KEW is a next-generation sequencing company focused on oncology. Their goal is to impact the entire cancer care continuum by expanding the accessibility and use of personalized medicine with the goal of assisting and empowering oncologists to make the right therapy decision for each patient. The KEW CANCERPLEX tests provide actionable, accurate, and timely information on patient-specific genomic data as it pertains to targeted cancer therapies and assist in the selection of appropriate trials in clinical development.
This project was a top to bottom brand refresh. We created a new identity and creative platform based on the idea of singling out the "one gene" that determines what targeted therapy each individual cancer patient will receive.